RxDoctor Payments Data

Matthew Ammerman, MD

Neurological Surgery · Washington, DCNPI 1871764258

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $86,750 of the $98,653 with a category attached, or 87.9%. Medtronic accounts for 99.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $26,280 and has fallen 99.5% since, to $122 in 2025. Among neurological surgery clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$98,653in general payments, 2019–2025

Across 93 payments — averaging $1060.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$98K
  • Johnson & Johnson$200
  • Kuros Biosciences USA, Inc$157
  • Boston Scientific$101
  • Globus Medical$68
  • Orthofix Medical, Inc.$49
  • plus $158 from 6 others

What the payments were for

  • Speaking & faculty fees$86,75088%
  • Travel & lodging$8,5449%
  • Food & beverage$3,3583%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,653 in reported general payments places this provider in the 95th percentile of 31 neurological surgery providers in District of Columbia.

See all neurological surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$96,418
Medicare patients
267
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tizanidine Hcl25$979
Gabapentin50$524
Methylprednisolone33$257
Celecoxib15$95
Tramadol Hcl17$47

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →